



## Clinical trial results:

**A Phase II, multi-center, double-blind, placebo-controlled, parallel-group, dose-response study to assess the safety and efficacy of CDP870/Certolizumab pegol, dosed subcutaneously in patients with active crohn's disease**

### Summary

|                          |                  |
|--------------------------|------------------|
| EudraCT number           | 2014-004399-42   |
| Trial protocol           | Outside EU/EEA   |
| Global end of trial date | 08 November 2007 |

### Results information

|                                |  |
|--------------------------------|--|
| Result version number          | v2 (current)   |
| This version publication date  | 24 September 2020  |
| First version publication date | 11 June 2015   |
| Version creation reason        | <ul style="list-style-type: none"><li>• Correction of full data set Alignment with final posting on ClinicalTrials.gov after NIH review.</li></ul> |

### Trial information

#### Trial identification

|                       |        |
|-----------------------|--------|
| Sponsor protocol code | C87037 |
|-----------------------|--------|

#### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT00291668 |
| WHO universal trial number (UTN)   | -           |

Notes:

### Sponsors

|                              |   |
|------------------------------|---|
| Sponsor organisation name    | UCB Japan Co., Ltd  |
| Sponsor organisation address | Shinjuku-ku, Tokyo, Japan, 160-0023   |
| Public contact               | Clinical Trial Registries and Results Disclosure, UCB BIOSCIENCES GmbH, +49 2173 4815 15, clinicaltrials@ucb.com  |
| Scientific contact           | Clinical Trial Registries and Results Disclosure, UCB BIOSCIENCES GmbH, +49 2173 48 15 15, clinicaltrials@ucb.com |

Notes:

### Paediatric regulatory details

|  |     |
|--|-----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No  |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No  |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |

Notes:

## Results analysis stage

|  |                  |
|--|------------------|
| Analysis stage                                       | Final            |
| Date of interim/final analysis                       | 26 August 2008   |
| Is this the analysis of the primary completion data? | No               |
| Global end of trial reached?                         | Yes              |
| Global end of trial date                             | 08 November 2007 |
| Was the trial ended prematurely?                     | No               |

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of the study was to estimate the dose response in subjects with active Crohn's Disease (CD), and to evaluate the efficacy of certolizumab pegol in these subjects.

Protection of trial subjects:

Not applicable

Background therapy:

Steroids, immunosuppressants, antibacterial agents, 5-ASA derivatives, antidiarrheal drugs, topical ano-rectal treatments, and laxative drugs/enemas were allowed concomitantly with no change in dosage and administration from the start of the observation period to Week 6.

Evidence for comparator:

Not applicable

|   |               |
|---|---------------|
| Actual start date of recruitment                          | 02 March 2006 |
| Long term follow-up planned                               | Yes           |
| Long term follow-up rationale                             | Safety        |
| Long term follow-up duration                              | 9 Months      |
| Independent data monitoring committee (IDMC) involvement? | No            |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |           |
|--------------------------------------|-----------|
| Country: Number of subjects enrolled | Japan: 94 |
| Worldwide total number of subjects   | 94        |
| EEA total number of subjects         | 0         |

Notes:

### Subjects enrolled per age group

|   |   |
|---|---|
| In utero                                  | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days)                      | 0 |
| Infants and toddlers (28 days-23 months)  | 0 |

|                           |    |
|---------------------------|----|
| Children (2-11 years)     | 0  |
| Adolescents (12-17 years) | 6  |
| Adults (18-64 years)      | 88 |
| From 65 to 84 years       | 0  |
| 85 years and over         | 0  |

## Subject disposition

### Recruitment

Recruitment details:

This study started to enroll subjects in March 2006 and concluded in November 2007.

### Pre-assignment

Screening details:

Participant Flow refers to the Safety Set, including all randomized subjects who received at least one dose of study medication (Placebo or Certolizumab Pegol).

### Period 1

|                              |                                |
|------------------------------|--------------------------------|
| Period 1 title               | Overall Study (overall period) |
| Is this the baseline period? | Yes                            |
| Allocation method            | Randomised - controlled        |
| Blinding used                | Double blind                   |
| Roles blinded                | Subject, Investigator, Carer   |

### Arms

|                              |         |
|------------------------------|---------|
| Are arms mutually exclusive? | Yes     |
| <b>Arm title</b>             | Placebo |

Arm description:

Subjects received two subcutaneous (sc) injections of Placebo on Weeks 0 (first dose), 2 and 4.

|  |                        |
|--|------------------------|
| Arm type                               | Placebo                |
| Investigational medicinal product name | Placebo                |
| Investigational medicinal product code | PBO                    |
| Other name                             |                        |
| Pharmaceutical forms                   | Solution for injection |
| Routes of administration               | Subcutaneous use       |

Dosage and administration details:

Subjects received two subcutaneous (sc) injections of Placebo on Weeks 0 (first dose), 2 and 4.

|                  |                           |
|------------------|---------------------------|
| <b>Arm title</b> | Certolizumab pegol 200 mg |
|------------------|---------------------------|

Arm description:

Subjects received one subcutaneous (sc) injection of 200 mg CZP and one injection of Placebo to maintain the study blind on Weeks 0 (first dose), 2 and 4.

|  |                        |
|--|------------------------|
| Arm type                               | Experimental           |
| Investigational medicinal product name | Certolizumab Pegol     |
| Investigational medicinal product code | CZP                    |
| Other name                             | Cimzia                 |
| Pharmaceutical forms                   | Solution for injection |
| Routes of administration               | Subcutaneous use       |

Dosage and administration details:

Subjects in the CZP 200 mg arm received one subcutaneous (sc) injection of 200 mg CZP and one injection of Placebo to maintain the study blind on Weeks 0 (first dose), 2 and 4.

Subjects in the CZP 400 mg arm received two subcutaneous (sc) injections of 200 mg CZP on Weeks 0 (first dose), 2 and 4.

|                  |                           |
|------------------|---------------------------|
| <b>Arm title</b> | Certolizumab pegol 400 mg |
|------------------|---------------------------|

Arm description:

Subjects received two subcutaneous (sc) injections of 200 mg CZP on Weeks 0 (first dose), 2 and 4.

|          |              |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

|  |                        |
|--|------------------------|
| Investigational medicinal product name | Certolizumab Pegol     |
| Investigational medicinal product code | CZP                    |
| Other name                             | Cimzia                 |
| Pharmaceutical forms                   | Solution for injection |
| Routes of administration               | Subcutaneous use       |

Dosage and administration details:

Subjects in the CZP 200 mg arm received one subcutaneous (sc) injection of 200 mg CZP and one injection of Placebo to maintain the study blind on Weeks 0 (first dose), 2 and 4.

Subjects in the CZP 400 mg arm received two subcutaneous (sc) injections of 200 mg CZP on Weeks 0 (first dose), 2 and 4.

| <b>Number of subjects in period 1</b>          | Placebo | Certolizumab pegol<br>200 mg | Certolizumab pegol<br>400 mg |
|--|---------|------------------------------|------------------------------|
| Started  | 32      | 30                           | 32                           |
| Completed                                      | 28      | 29                           | 31                           |
| Not completed                                  | 4       | 1                            | 1                            |
| SAE, non-fatal + AE, non-serious,<br>non-fatal | 1       | -                            | -                            |
| AE, non-serious, non-fatal                     | 1       | -                            | -                            |
| SAE, non-fatal                                 | 1       | 1                            | 1                            |
| Lack of efficacy                               | 1       | -                            | -                            |

## Baseline characteristics

### Reporting groups

|  |                           |
|--|---------------------------|
| Reporting group title  | Placebo                   |
| Reporting group description:   |                           |
| Subjects received two subcutaneous (sc) injections of Placebo on Weeks 0 (first dose), 2 and 4.  |                           |
| Reporting group title  | Certolizumab pegol 200 mg |
| Reporting group description:   |                           |
| Subjects received one subcutaneous (sc) injection of 200 mg CZP and one injection of Placebo to maintain the study blind on Weeks 0 (first dose), 2 and 4. |                           |
| Reporting group title  | Certolizumab pegol 400 mg |
| Reporting group description:   |                           |
| Subjects received two subcutaneous (sc) injections of 200 mg CZP on Weeks 0 (first dose), 2 and 4.   |                           |

| Reporting group values                | Placebo | Certolizumab pegol 200 mg | Certolizumab pegol 400 mg |
|---------------------------------------|---------|---------------------------|---------------------------|
| Number of subjects                    | 32      | 30                        | 32                        |
| Age categorical<br>Units: Subjects    |         |                           |                           |
| <=18 years                            | 2       | 2                         | 2                         |
| Between 18 and 65 years               | 30      | 28                        | 30                        |
| >=65 years                            | 0       | 0                         | 0                         |
| Age Continuous<br>Units: years        |         |                           |                           |
| arithmetic mean                       | 30.6    | 32.7                      | 31.4                      |
| standard deviation                    | ± 8.16  | ± 9.34                    | ± 8.27                    |
| Gender Categorical<br>Units: Subjects |         |                           |                           |
| Male                                  | 26      | 22                        | 25                        |
| Female                                | 6       | 8                         | 7                         |

| Reporting group values                | Total |  |  |
|---------------------------------------|-------|--|--|
| Number of subjects                    | 94    |  |  |
| Age categorical<br>Units: Subjects    |       |  |  |
| <=18 years                            | 6     |  |  |
| Between 18 and 65 years               | 88    |  |  |
| >=65 years                            | 0     |  |  |
| Age Continuous<br>Units: years        |       |  |  |
| arithmetic mean                       |       |  |  |
| standard deviation                    | -     |  |  |
| Gender Categorical<br>Units: Subjects |       |  |  |
| Male                                  | 73    |  |  |
| Female                                | 21    |  |  |

## End points

### End points reporting groups

|   |   |
|---|---|
| Reporting group title   | Placebo   |
| Reporting group description:  |   |
| Subjects received two subcutaneous (sc) injections of Placebo on Weeks 0 (first dose), 2 and 4.   |   |
| Reporting group title   | Certolizumab pegol 200 mg                       |
| Reporting group description:  |   |
| Subjects received one subcutaneous (sc) injection of 200 mg CZP and one injection of Placebo to maintain the study blind on Weeks 0 (first dose), 2 and 4.  |   |
| Reporting group title   | Certolizumab pegol 400 mg                       |
| Reporting group description:  |   |
| Subjects received two subcutaneous (sc) injections of 200 mg CZP on Weeks 0 (first dose), 2 and 4.  |   |
| Subject analysis set title  | Full Analysis Set (Placebo treated subjects)    |
| Subject analysis set type   | Full analysis                                   |
| Subject analysis set description:   |   |
| The Full Analysis Set was defined as the subjects who were randomized and allocated to study medication, but excluded the following subjects as determined by data review prior to unblinding:  |   |
| <ul style="list-style-type: none"><li>- Subjects with Good Clinical Practice (GCP) violations</li><li>- Subjects who were not diagnosed (definitely) with Crohn's Disease</li><li>- Subjects who received no dose of study medication</li><li>- Subjects with no data after randomization</li></ul> |   |
| Subject analysis set title  | Full Analysis Set (CZP 200 mg treated subjects) |
| Subject analysis set type   | Full analysis                                   |
| Subject analysis set description:   |   |
| The Full Analysis Set was defined as the subjects who were randomized and allocated to study medication, but excluded the following subjects as determined by data review prior to unblinding:  |   |
| <ul style="list-style-type: none"><li>- Subjects with Good Clinical Practice (GCP) violations</li><li>- Subjects who were not diagnosed (definitely) with Crohn's Disease</li><li>- Subjects who received no dose of study medication</li><li>- Subjects with no data after randomization</li></ul> |   |
| Subject analysis set title  | Full Analysis Set (CZP 400 mg treated subjects) |
| Subject analysis set type   | Full analysis                                   |
| Subject analysis set description:   |   |
| The Full Analysis Set was defined as the subjects who were randomized and allocated to study medication, but excluded the following subjects as determined by data review prior to unblinding:  |   |
| <ul style="list-style-type: none"><li>- Subjects with Good Clinical Practice (GCP) violations</li><li>- Subjects who were not diagnosed (definitely) with Crohn's Disease</li><li>- Subjects who received no dose of study medication</li><li>- Subjects with no data after randomization</li></ul> |   |

### Primary: Crohn's Disease Activity Index (CDAI) response (clinical response or remission) at Week 6

|  |  |
|--|--|
| End point title  | Crohn's Disease Activity Index (CDAI) response (clinical response or remission) at Week 6 <sup>[1]</sup> |
| End point description:   |  |
| CDAI Response is presented as the percentage of subjects with clinical response at Week 6 or remission at Week 6. Clinical response is defined as at least a 100-point decrease from the Week 0 CDAI score, where change = (CDAI score at Week 6) – (CDAI score at Week 0). Remission is defined as a CDAI of ≤ 150 at Week 6. |  |
| End point type   | Primary  |
| End point timeframe:   |  |
| Baseline, Week 6   |  |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No formal statistical hypothesis testing was planned for this study. Results were summarized in tables as descriptive statistics only.

| End point values                 | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|----------------------------------|--|---|---|--|
| Subject group type               | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed      | 32   | 30  | 31  |  |
| Units: percentage of subjects    |  |   |   |  |
| number (confidence interval 95%) |  |   |   |  |
| Percentage of Subjects (95 % CI) | 25 (10 to 40)                                | 43.3 (25.6 to 61.1)                             | 48.4 (30.8 to 66)                               |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Crohn's Disease Activity Index (CDAI) score at Week 2

|                        |  |
|------------------------|--|
| End point title        | Crohn's Disease Activity Index (CDAI) score at Week 2  |
| End point description: | The Crohn's Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn's Disease. The CDAI score can range from 0-600 (600 indicating the worst disease). It is the sum of 8 subscores, only the summary score is used here. A CDAI score of 150 or less is considered as remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity. |
| End point type         | Secondary  |
| End point timeframe:   |  |
| Week 2                 |  |

| End point values                     | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|--------------------------------------|--|---|---|--|
| Subject group type                   | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed          | 29   | 29  | 31  |  |
| Units: units on a scale              |  |   |   |  |
| arithmetic mean (standard deviation) |  |   |   |  |
| arithmetic mean (standard deviation) | 255.9 (± 68.02)                              | 214.2 (± 83.51)                                 | 224.9 (± 85.05)                                 |  |

## Statistical analyses

No statistical analyses for this end point



**Secondary: Crohn's Disease Activity Index (CDAI) score at Week 4**

|                 |   |
|-----------------|---|
| End point title | Crohn's Disease Activity Index (CDAI) score at Week 4 |
|-----------------|---|

End point description:

The Crohn's Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn's Disease. The CDAI score can range from 0-600 (600 indicating the worst disease). It is the sum of 8 subscores, only the summary score is used here. A CDAI score of 150 or less is considered as remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 4

| End point values                     | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|--------------------------------------|--|---|---|--|
| Subject group type                   | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed          | 28   | 27  | 30  |  |
| Units: units on a scale              |  |   |   |  |
| arithmetic mean (standard deviation) |  |   |   |  |
| arithmetic mean (standard deviation) | 243.1 (± 68.57)                              | 199.7 (± 91.25)                                 | 204.6 (± 75.1)                                  |  |

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Crohn's Disease Activity Index (CDAI) score at Week 6**

|                 |   |
|-----------------|---|
| End point title | Crohn's Disease Activity Index (CDAI) score at Week 6 |
|-----------------|---|

End point description:

The Crohn's Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn's Disease. The CDAI score can range from 0-600 (600 indicating the worst disease). It is the sum of 8 subscores, only the summary score is used here. A CDAI score of 150 or less is considered as remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 6

| End point values                     | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|--------------------------------------|--|---|---|--|
| Subject group type                   | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed          | 28   | 27  | 30  |  |
| Units: units on a scale              |  |   |   |  |
| arithmetic mean (standard deviation) |  |   |   |  |

|                                      |                 |               |                 |  |
|--------------------------------------|-----------------|---------------|-----------------|--|
| arithmetic mean (standard deviation) | 232.4 (± 89.28) | 211 (± 99.91) | 198.1 (± 87.88) |  |
|--------------------------------------|-----------------|---------------|-----------------|--|

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of subjects who achieve CDAI response at Week 2

|                 |  |
|-----------------|--|
| End point title | Percentage of subjects who achieve CDAI response at Week 2 |
|-----------------|--|

End point description:

CDAI Response at Week 2 is defined as clinical response at Week 2 or remission at Week 2. Clinical response is defined as at least a 100-point decrease from the Week 0 CDAI score, where change = (CDAI score at Week 2) – (CDAI score at Week 0). Remission is defined as a CDAI score of ≤ 150 points.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Week 2

| End point values                 | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|----------------------------------|--|---|---|--|
| Subject group type               | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed      | 32   | 30  | 31  |  |
| Units: percentage of subjects    |  |   |   |  |
| number (confidence interval 95%) |  |   |   |  |
| Percentage of Subjects (95 % CI) | 15.6 (3 to 28.2)                             | 40 (22.5 to 57.5)                               | 32.3 (15.8 to 48.7)                             |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of subjects who achieve CDAI response at Week 4

|                 |  |
|-----------------|--|
| End point title | Percentage of subjects who achieve CDAI response at Week 4 |
|-----------------|--|

End point description:

CDAI Response at Week 4 is defined as clinical response at Week 4 or remission at Week 4. Clinical response is defined as at least a 100-point decrease from the Week 0 CDAI score, where change = (CDAI score at Week 4) – (CDAI score at Week 0). Remission is defined as a CDAI score of ≤ 150 points.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Week 4

| End point values                 | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|----------------------------------|--|---|---|--|
| Subject group type               | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed      | 32   | 30  | 31  |  |
| Units: percentage of subjects    |  |   |   |  |
| number (confidence interval 95%) |  |   |   |  |
| Percentage of Subjects (95 % CI) | 21.9 (7.6 to 36.2)                           | 46.7 (28.8 to 64.5)                             | 38.7 (21.6 to 55.9)                             |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of subjects who achieve a reduction in CDAI scores of at least 70 points at Week 2

|  |   |
|--|---|
| End point title  | Percentage of subjects who achieve a reduction in CDAI scores of at least 70 points at Week 2 |
| End point description:   |   |
| The Crohn's Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity. |   |
| End point type   | Secondary   |
| End point timeframe:   |   |
| Baseline, Week 2   |   |

| End point values                 | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|----------------------------------|--|---|---|--|
| Subject group type               | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed      | 32   | 30  | 31  |  |
| Units: percentage of subjects    |  |   |   |  |
| number (confidence interval 95%) |  |   |   |  |
| Percentage of Subjects (95 % CI) | 28.1 (12.5 to 43.7)                          | 46.7 (28.8 to 64.5)                             | 45.2 (27.6 to 62.7)                             |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of subjects who achieve a reduction in CDAI scores of at least 70 points at Week 4

|  |   |
|--|---|
| End point title  | Percentage of subjects who achieve a reduction in CDAI scores of at least 70 points at Week 4 |
| End point description:<br>The Crohn's Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity. |   |
| End point type   | Secondary   |
| End point timeframe:<br>Baseline, Week 4   |   |

| End point values                 | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|----------------------------------|--|---|---|--|
| Subject group type               | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed      | 32   | 30  | 31  |  |
| Units: percentage of subjects    |  |   |   |  |
| number (confidence interval 95%) |  |   |   |  |
| Percentage of Subjects (95 % CI) | 25 (10 to 40)                                | 56.7 (38.9 to 74.4)                             | 54.8 (37.3 to 72.4)                             |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of subjects who achieve a reduction in CDAI scores of at least 70 points at Week 6

|  |   |
|--|---|
| End point title  | Percentage of subjects who achieve a reduction in CDAI scores of at least 70 points at Week 6 |
| End point description:<br>The Crohn's Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates disease remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity. |   |
| End point type   | Secondary   |
| End point timeframe:<br>Baseline, Week 6   |   |

| End point values                 | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|----------------------------------|--|---|---|--|
| Subject group type               | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed      | 32   | 30  | 31  |  |
| Units: percentage of subjects    |  |   |   |  |
| number (confidence interval 95%) |  |   |   |  |
| Percentage of Subjects (95 % CI) | 43.8 (26.6 to 60.9)                          | 53.3 (35.5 to 71.2)                             | 61.3 (44.1 to 78.4)                             |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of subjects who achieve remission (CDAI ≤ 150) at Week 2

|                 |   |
|-----------------|---|
| End point title | Percentage of subjects who achieve remission (CDAI ≤ 150) at Week 2 |
|-----------------|---|

End point description:

Remission at Week 2 is defined as a CDAI score ≤ 150 points at Week 2.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 2

| End point values                 | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|----------------------------------|--|---|---|--|
| Subject group type               | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed      | 32   | 30  | 31  |  |
| Units: percentage of subjects    |  |   |   |  |
| number (confidence interval 95%) |  |   |   |  |
| Percentage of Subjects (95 % CI) | 3.1 (0 to 9.2)                               | 20 (5.7 to 34.3)                                | 16.1 (3.2 to 29.1)                              |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of subjects who achieve remission (CDAI ≤ 150) at Week 4

|                 |   |
|-----------------|---|
| End point title | Percentage of subjects who achieve remission (CDAI ≤ 150) at Week 4 |
|-----------------|---|

End point description:

Remission at Week 4 is defined as a CDAI score ≤ 150 points at Week 4.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 4

| End point values                 | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|----------------------------------|--|---|---|--|
| Subject group type               | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed      | 32   | 30  | 31  |  |
| Units: percentage of subjects    |  |   |   |  |
| number (confidence interval 95%) |  |   |   |  |
| Percentage of Subjects (95 % CI) | 6.3 (0 to 14.6)                              | 26.7 (10.8 to 42.5)                             | 22.6 (7.9 to 37.3)                              |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of subjects who achieve remission (CDAI ≤ 150) at Week 6

|  |   |
|--|---|
| End point title  | Percentage of subjects who achieve remission (CDAI ≤ 150) at Week 6 |
| End point description:<br>Remission at Week 6 is defined as a CDAI score ≤ 150 points at Week 6. |   |
| End point type   | Secondary   |
| End point timeframe:<br>Week 6   |   |

| End point values                 | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|----------------------------------|--|---|---|--|
| Subject group type               | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed      | 32   | 30  | 31  |  |
| Units: percentage of subjects    |  |   |   |  |
| number (confidence interval 95%) |  |   |   |  |
| Percentage of Subjects (95 % CI) | 15.6 (3 to 28.2)                             | 26.7 (10.8 to 42.5)                             | 32.3 (15.8 to 48.7)                             |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of subjects who achieve clinical response (reduction in CDAI scores of at least 100 points) at Week 2

|   |  |
|---|--|
| End point title   | Percentage of subjects who achieve clinical response (reduction in CDAI scores of at least 100 points) at Week 2 |
| End point description:<br>Clinical response is defined as at least a 100-point decrease from the Week 0 CDAI score, where change = (CDAI score at Week 2) – (CDAI score at Week 0). |  |
| End point type  | Secondary  |

End point timeframe:

Baseline, Week 2

| End point values                 | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|----------------------------------|--|---|---|--|
| Subject group type               | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed      | 32   | 30  | 31  |  |
| Units: percentage of subjects    |  |   |   |  |
| number (confidence interval 95%) |  |   |   |  |
| Percentage of Subjects (95 % CI) | 15.6 (3 to 28.2)                             | 36.7 (19.4 to 53.9)                             | 29 (13.1 to 45)                                 |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of subjects who achieve clinical response (reduction in CDAI scores of at least 100 points) at Week 4

|                 |  |
|-----------------|--|
| End point title | Percentage of subjects who achieve clinical response (reduction in CDAI scores of at least 100 points) at Week 4 |
|-----------------|--|

End point description:

Clinical response is defined as at least a 100-point decrease from the Week 0 CDAI score, where change = (CDAI score at Week 4) – (CDAI score at Week 0).

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Week 4

| End point values                 | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|----------------------------------|--|---|---|--|
| Subject group type               | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed      | 32   | 30  | 31  |  |
| Units: percentage of subjects    |  |   |   |  |
| number (confidence interval 95%) |  |   |   |  |
| Percentage of Subjects (95 % CI) | 18.8 (5.2 to 32.3)                           | 36.7 (19.4 to 53.9)                             | 32.3 (15.8 to 48.7)                             |  |

### Statistical analyses

No statistical analyses for this end point

**Secondary: Percentage of subjects who achieve clinical response (reduction in CDAI scores of at least 100 points) at Week 6**

|   |  |
|---|--|
| End point title   | Percentage of subjects who achieve clinical response (reduction in CDAI scores of at least 100 points) at Week 6 |
| End point description:<br>Clinical response is defined as at least a 100-point decrease from the Week 0 CDAI score, where change = (CDAI score at Week 6) – (CDAI score at Week 0). |  |
| End point type  | Secondary  |
| End point timeframe:<br>Baseline, Week 6  |  |

| End point values                 | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|----------------------------------|--|---|---|--|
| Subject group type               | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed      | 32   | 30  | 31  |  |
| Units: percentage of subjects    |  |   |   |  |
| number (confidence interval 95%) |  |   |   |  |
| Percentage of Subjects (95 % CI) | 21.9 (7.6 to 36.2)                           | 36.7 (19.4 to 53.9)                             | 41.9 (24.6 to 59.3)                             |  |

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Inflammatory Bowel Disease Questionnaire (IBDQ) global score at Week 2**

|   |  |
|---|--|
| End point title   | Inflammatory Bowel Disease Questionnaire (IBDQ) global score at Week 2 |
| End point description:<br>The IBDQ global score is calculated as the sum of the responses (each ranging from 1 to 7) to all 32 questions on the IBDQ and can therefore range from 32 to 224. A higher score indicates a better quality of life. |  |
| End point type  | Secondary  |
| End point timeframe:<br>Week 2  |  |

| End point values                     | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|--------------------------------------|--|---|---|--|
| Subject group type                   | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed          | 29   | 29  | 31  |  |
| Units: units on a scale              |  |   |   |  |
| arithmetic mean (standard deviation) |  |   |   |  |



|                                      |                 |                 |                 |  |
|--------------------------------------|-----------------|-----------------|-----------------|--|
| arithmetic mean (standard deviation) | 171.3 (± 22.45) | 166.1 (± 22.14) | 169.7 (± 23.24) |  |
|--------------------------------------|-----------------|-----------------|-----------------|--|

## Statistical analyses

No statistical analyses for this end point

## Secondary: Inflammatory Bowel Disease Questionnaire (IBDQ) global score at Week 4

|   |  |
|---|--|
| End point title   | Inflammatory Bowel Disease Questionnaire (IBDQ) global score at Week 4 |
| End point description:<br>The IBDQ global score is calculated as the sum of the responses (each ranging from 1 to 7) to all 32 questions on the IBDQ and can therefore range from 32 to 224. A higher score indicates a better quality of life. |  |
| End point type  | Secondary  |
| End point timeframe:<br>Week 4  |  |

| End point values                     | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|--------------------------------------|--|---|---|--|
| Subject group type                   | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed          | 28   | 27  | 30  |  |
| Units: units on a scale              |  |   |   |  |
| arithmetic mean (standard deviation) |  |   |   |  |
| arithmetic mean (standard deviation) | 172.6 (± 24.04)                              | 169.4 (± 21.75)                                 | 170.3 (± 23.72)                                 |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Inflammatory Bowel Disease Questionnaire (IBDQ) global score at Week 6

|   |  |
|---|--|
| End point title   | Inflammatory Bowel Disease Questionnaire (IBDQ) global score at Week 6 |
| End point description:<br>The IBDQ global score is calculated as the sum of the responses (each ranging from 1 to 7) to all 32 questions on the IBDQ and can therefore range from 32 to 224. A higher score indicates a better quality of life. |  |
| End point type  | Secondary  |
| End point timeframe:<br>Week 6  |  |

| End point values                     | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|--------------------------------------|--|---|---|--|
| Subject group type                   | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed          | 28   | 27  | 30  |  |
| Units: units on a scale              |  |   |   |  |
| arithmetic mean (standard deviation) |  |   |   |  |
| arithmetic mean (standard deviation) | 173.1 (± 25.49)                              | 165.6 (± 23.25)                                 | 170.8 (± 24.54)                                 |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Inflammatory Bowel Disease Questionnaire (IBDQ) domain scores at Week 2

|  |   |
|--|---|
| End point title  | Inflammatory Bowel Disease Questionnaire (IBDQ) domain scores at Week 2 |
| End point description:   |   |
| The total IBDQ score consists of 32 questions, each ranging from 1 to 7, with higher scores indicating a better quality of life.   |   |
| There are 4 IBDQ Domain Scores:  |   |
| <ul style="list-style-type: none"> <li>- Bowel Symptoms Domain Score, ranging from 10 to 70 (10 questions ranging from 1 to 7)</li> <li>- Systemic Symptoms Domain Score, ranging from 5 to 35 (5 questions ranging from 1 to 7)</li> <li>- Emotional Function Domain Score, ranging from 12 to 84 (12 questions ranging from 1 to 7)</li> <li>- Social Function Domain Score, ranging from 5 to 35 (5 questions ranging from 1 to 7)</li> </ul> |   |
| End point type   | Secondary   |
| End point timeframe:   |   |
| Week 2   |   |

| End point values                               | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|--|--|---|---|--|
| Subject group type                             | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed                    | 32   | 30  | 31  |  |
| Units: units on a scale                        |  |   |   |  |
| arithmetic mean (standard deviation)           |  |   |   |  |
| Bowel Symptoms Domain Score (n=29, 29, 31)     | 54.4 (± 7.17)                                | 53.4 (± 8.18)                                   | 54.7 (± 8.77)                                   |  |
| Systemic Symptoms Domain Score (n=29, 29, 31)  | 22.4 (± 5.01)                                | 22.4 (± 5.17)                                   | 22.7 (± 4.51)                                   |  |
| Emotional Function Domain Score (n=29, 29, 31) | 65.3 (± 8.91)                                | 62.3 (± 9.54)                                   | 63.3 (± 8.53)                                   |  |
| Social Function Domain Score (n=28, 29, 31)    | 29.4 (± 5.64)                                | 28 (± 4.33)                                     | 29 (± 5.03)                                     |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Inflammatory Bowel Disease Questionnaire (IBDQ) domain scores at Week 4

|                 |   |
|-----------------|---|
| End point title | Inflammatory Bowel Disease Questionnaire (IBDQ) domain scores at Week 4 |
|-----------------|---|

End point description:

The total IBDQ score consists of 32 questions, each ranging from 1 to 7, with higher scores indicating a better quality of life.

There are 4 IBDQ Domain Scores:

- Bowel Symptoms Domain Score, ranging from 10 to 70 (10 questions ranging from 1 to 7)
- Systemic Symptoms Domain Score, ranging from 5 to 35 (5 questions ranging from 1 to 7)
- Emotional Function Domain Score, ranging from 12 to 84 (12 questions ranging from 1 to 7)
- Social Function Domain Score, ranging from 5 to 35 (5 questions ranging from 1 to 7)

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 4

| End point values                               | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|--|--|---|---|--|
| Subject group type                             | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed                    | 32   | 30  | 31  |  |
| Units: units on a scale                        |  |   |   |  |
| arithmetic mean (standard deviation)           |  |   |   |  |
| Bowel Symptoms Domain Score (n=28, 27, 30)     | 55.4 (± 7.22)                                | 54 (± 9)  | 55.5 (± 8.04)                                   |  |
| Systemic Symptoms Domain Score (n=28, 27, 30)  | 23.3 (± 5.49)                                | 23.4 (± 4.21)                                   | 22.9 (± 4.44)                                   |  |
| Emotional Function Domain Score (n=28, 27, 30) | 65.3 (± 8.85)                                | 63.1 (± 8.9)                                    | 63.2 (± 9.55)                                   |  |
| Social Function Domain Score (n=27, 27, 30)    | 28.8 (± 6.73)                                | 28.9 (± 4.82)                                   | 28.7 (± 5.62)                                   |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Inflammatory Bowel Disease Questionnaire (IBDQ) domain scores at Week 6

|                 |   |
|-----------------|---|
| End point title | Inflammatory Bowel Disease Questionnaire (IBDQ) domain scores at Week 6 |
|-----------------|---|

**End point description:**

The total IBDQ score consists of 32 questions, each ranging from 1 to 7, with higher scores indicating a better quality of life.

There are 4 IBDQ Domain Scores:

- Bowel Symptoms Domain Score, ranging from 10 to 70 (10 questions ranging from 1 to 7)
- Systemic Symptoms Domain Score, ranging from 5 to 35 (5 questions ranging from 1 to 7)
- Emotional Function Domain Score, ranging from 12 to 84 (12 questions ranging from 1 to 7)
- Social Function Domain Score, ranging from 5 to 35 (5 questions ranging from 1 to 7)

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 6

| End point values                                | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|---|--|---|---|--|
| Subject group type                              | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed                     | 32   | 30  | 31  |  |
| Units: units on a scale                         |  |   |   |  |
| arithmetic mean (standard deviation)            |  |   |   |  |
| Bowel Symptoms Domain Score (n=28, 27, 30 )     | 55.4 (± 7.77)                                | 51.8 (± 8.44)                                   | 55.8 (± 8.43)                                   |  |
| Systemic Symptoms Domain Score (n= 28, 27, 30)  | 23.3 (± 6.74)                                | 22.4 (± 4.49)                                   | 23.4 (± 4.62)                                   |  |
| Emotional Function Domain Score (n= 28, 27, 30) | 65.3 (± 8.76)                                | 63.2 (± 9.45)                                   | 62.1 (± 10.43)                                  |  |
| Social Function Domain Score (n= 27, 27, 30)    | 29.2 (± 6.48)                                | 28.1 (± 5.69)                                   | 29.5 (± 5.09)                                   |  |

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Concentration of C-reactive Protein (CRP) Value at Week 2**

|                 |   |
|-----------------|---|
| End point title | Concentration of C-reactive Protein (CRP) Value at Week 2 |
|-----------------|---|

End point description:

CRP data for subjects receiving rescue medication were excluded.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 2

| End point values            | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|-----------------------------|--|---|---|--|
| Subject group type          | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed | 29   | 29  | 31  |  |
| Units: mg/L                 |  |   |   |  |

|  |                       |                       |                       |  |
|--|-----------------------|-----------------------|-----------------------|--|
| geometric mean (confidence interval 95%) |                       |                       |                       |  |
| Geometric Mean (95% CI)                  | 22.15 (15.43 to 31.8) | 13.58 (9.45 to 19.52) | 13.86 (9.11 to 21.09) |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Concentration of C-reactive Protein (CRP) Value at Week 4

|  |   |
|--|---|
| End point title  | Concentration of C-reactive Protein (CRP) Value at Week 4 |
| End point description:<br>CRP data for subjects receiving rescue medication were excluded. |   |
| End point type   | Secondary   |
| End point timeframe:<br>Week 4   |   |

| End point values                         | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|--|--|---|---|--|
| Subject group type                       | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed              | 28   | 27  | 30  |  |
| Units: mg/L                              |  |   |   |  |
| geometric mean (confidence interval 95%) |  |   |   |  |
| Geometric Mean (95% CI)                  | 23.47 (16.02 to 34.4)                        | 12.87 (8.56 to 19.36)                           | 12.02 (8.68 to 16.65)                           |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Concentration of C-reactive Protein (CRP) Value at Week 6

|  |   |
|--|---|
| End point title  | Concentration of C-reactive Protein (CRP) Value at Week 6 |
| End point description:<br>CRP data for subjects receiving rescue medication were excluded. |   |
| End point type   | Secondary   |
| End point timeframe:<br>Week 6   |   |

| End point values                         | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|--|--|---|---|--|
| Subject group type                       | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed              | 28   | 27  | 30  |  |
| Units: mg/L                              |  |   |   |  |
| geometric mean (confidence interval 95%) |  |   |   |  |
| Geometric Mean (95% CI)                  | 23.32 (16.95 to 32.07)                       | 15.1 (9.46 to 24.11)                            | 12.62 (8.79 to 18.11)                           |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: C-reactive protein (CRP) Ratio to Baseline at Week 2

|  |  |
|--|--|
| End point title  | C-reactive protein (CRP) Ratio to Baseline at Week 2 |
| End point description:<br>CRP data for subjects receiving rescue medication were excluded. |  |
| End point type   | Secondary  |
| End point timeframe:<br>Baseline, Week 2   |  |

| End point values                         | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|--|--|---|---|--|
| Subject group type                       | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed              | 29   | 29  | 31  |  |
| Units: ratio                             |  |   |   |  |
| geometric mean (confidence interval 95%) |  |   |   |  |
| Geometric Mean (95% CI)                  | 0.85 (0.64 to 1.13)                          | 0.58 (0.42 to 0.8)                              | 0.5 (0.35 to 0.72)                              |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: C-reactive protein (CRP) Ratio to Baseline at Week 4

|  |  |
|--|--|
| End point title  | C-reactive protein (CRP) Ratio to Baseline at Week 4 |
| End point description:<br>CRP data for subjects receiving rescue medication were excluded. |  |
| End point type   | Secondary  |
| End point timeframe:<br>Baseline, Week 4   |  |

| End point values                         | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|--|--|---|---|--|
| Subject group type                       | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed              | 28   | 27  | 30  |  |
| Units: ratio                             |  |   |   |  |
| geometric mean (confidence interval 95%) |  |   |   |  |
| Geometric Mean (95% CI)                  | 1.04 (0.83 to 1.31)                          | 0.53 (0.37 to 0.76)                             | 0.44 (0.32 to 0.6)                              |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: C-reactive protein (CRP) Ratio to Baseline at Week 6

|                        |  |
|------------------------|--|
| End point title        | C-reactive protein (CRP) Ratio to Baseline at Week 6             |
| End point description: | CRP data for subjects receiving rescue medication were excluded. |
| End point type         | Secondary  |
| End point timeframe:   |  |
| Baseline, Week 6       |  |

| End point values                         | Full Analysis Set (Placebo treated subjects) | Full Analysis Set (CZP 200 mg treated subjects) | Full Analysis Set (CZP 400 mg treated subjects) |  |
|--|--|---|---|--|
| Subject group type                       | Subject analysis set                         | Subject analysis set                            | Subject analysis set                            |  |
| Number of subjects analysed              | 28   | 27  | 30  |  |
| Units: ratio                             |  |   |   |  |
| geometric mean (confidence interval 95%) |  |   |   |  |
| Geometric Mean (95% CI)                  | 1.03 (0.85 to 1.25)                          | 0.63 (0.4 to 0.98)                              | 0.46 (0.32 to 0.66)                             |  |

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse Events were collected from the time of signing the informed consent through the last Observation (up to 28 weeks).

Adverse event reporting additional description:

Adverse Events refer to the Safety Population, including all randomized subjects who received at least one dose of study medication (Placebo or Certolizumab Pegol).

|                 |                |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |     |
|--------------------|-----|
| Dictionary version | 9.0 |
|--------------------|-----|

### Reporting groups

|                       |         |
|-----------------------|---------|
| Reporting group title | Placebo |
|-----------------------|---------|

Reporting group description:

Subjects received two subcutaneous (sc) injections of Placebo on Weeks 0 (first dose), 2 and 4.

|                       |                           |
|-----------------------|---------------------------|
| Reporting group title | Certolizumab pegol 400 mg |
|-----------------------|---------------------------|

Reporting group description:

Subjects received two subcutaneous (sc) injections of 200 mg CZP on Weeks 0 (first dose), 2 and 4.

|                       |                           |
|-----------------------|---------------------------|
| Reporting group title | Certolizumab pegol 200 mg |
|-----------------------|---------------------------|

Reporting group description:

Subjects received one subcutaneous (sc) injection of 200 mg CZP and one injection of Placebo to maintain the study blind on Weeks 0 (first dose), 2 and 4.

| Serious adverse events                               | Placebo        | Certolizumab pegol 400 mg | Certolizumab pegol 200 mg |
|--|----------------|---------------------------|---------------------------|
| Total subjects affected by serious adverse events    |                |                           |                           |
| subjects affected / exposed                          | 3 / 32 (9.38%) | 3 / 32 (9.38%)            | 1 / 30 (3.33%)            |
| number of deaths (all causes)                        | 0              | 0                         | 0                         |
| number of deaths resulting from adverse events       | 0              | 0                         | 0                         |
| Blood and lymphatic system disorders                 |                |                           |                           |
| Disseminated intravascular coagulation               |                |                           |                           |
| subjects affected / exposed                          | 0 / 32 (0.00%) | 1 / 32 (3.13%)            | 0 / 30 (0.00%)            |
| occurrences causally related to treatment / all      | 0 / 0          | 1 / 1                     | 0 / 0                     |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0                     | 0 / 0                     |
| General disorders and administration site conditions |                |                           |                           |
| Pyrexia  |                |                           |                           |
| subjects affected / exposed                          | 0 / 32 (0.00%) | 2 / 32 (6.25%)            | 0 / 30 (0.00%)            |
| occurrences causally related to treatment / all      | 0 / 0          | 2 / 2                     | 0 / 0                     |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0                     | 0 / 0                     |
| Gastrointestinal disorders                           |                |                           |                           |



|   |                |                |                |
|---|----------------|----------------|----------------|
| Crohn's disease                                 |                |                |                |
| subjects affected / exposed                     | 3 / 32 (9.38%) | 0 / 32 (0.00%) | 0 / 30 (0.00%) |
| occurrences causally related to treatment / all | 2 / 3          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Abdominal pain                                  |                |                |                |
| subjects affected / exposed                     | 0 / 32 (0.00%) | 1 / 32 (3.13%) | 0 / 30 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 1 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Gastrointestinal haemorrhage                    |                |                |                |
| subjects affected / exposed                     | 1 / 32 (3.13%) | 0 / 32 (0.00%) | 0 / 30 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Peritonitis                                     |                |                |                |
| subjects affected / exposed                     | 1 / 32 (3.13%) | 0 / 32 (0.00%) | 0 / 30 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Respiratory, thoracic and mediastinal disorders |                |                |                |
| Pneumonia aspiration                            |                |                |                |
| subjects affected / exposed                     | 0 / 32 (0.00%) | 0 / 32 (0.00%) | 1 / 30 (3.33%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 3 / 3          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Infections and infestations                     |                |                |                |
| Sepsis  |                |                |                |
| subjects affected / exposed                     | 0 / 32 (0.00%) | 1 / 32 (3.13%) | 0 / 30 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 1 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events                            | Placebo          | Certolizumab pegol<br>400 mg | Certolizumab pegol<br>200 mg |
|---|------------------|------------------------------|------------------------------|
| Total subjects affected by non-serious adverse events |                  |                              |                              |
| subjects affected / exposed                           | 16 / 32 (50.00%) | 14 / 32 (43.75%)             | 11 / 30 (36.67%)             |
| Investigations  |                  |                              |                              |

|  |   |   |   |
|--|---|---|---|
| White blood cell count decreased<br>subjects affected / exposed<br>occurrences (all)   | 0 / 32 (0.00%)<br>0   | 2 / 32 (6.25%)<br>2   | 0 / 30 (0.00%)<br>0   |
| Nervous system disorders<br>Headache<br>subjects affected / exposed<br>occurrences (all)   | 2 / 32 (6.25%)<br>2   | 1 / 32 (3.13%)<br>1   | 0 / 30 (0.00%)<br>0   |
| General disorders and administration<br>site conditions<br>Pyrexia<br>subjects affected / exposed<br>occurrences (all)   | 2 / 32 (6.25%)<br>2   | 1 / 32 (3.13%)<br>1   | 2 / 30 (6.67%)<br>3   |
| Gastrointestinal disorders<br>Nausea<br>subjects affected / exposed<br>occurrences (all)<br><br>Vomiting<br>subjects affected / exposed<br>occurrences (all)   | 1 / 32 (3.13%)<br>1<br><br>0 / 32 (0.00%)<br>0                            | 2 / 32 (6.25%)<br>2<br><br>1 / 32 (3.13%)<br>1                            | 2 / 30 (6.67%)<br>3<br><br>2 / 30 (6.67%)<br>3                            |
| Hepatobiliary disorders<br>Hepatic function abnormal<br>subjects affected / exposed<br>occurrences (all)   | 2 / 32 (6.25%)<br>2   | 0 / 32 (0.00%)<br>0   | 0 / 30 (0.00%)<br>0   |
| Respiratory, thoracic and mediastinal<br>disorders<br>Pharyngolaryngeal pain<br>subjects affected / exposed<br>occurrences (all)<br><br>Pharynx discomfort<br>subjects affected / exposed<br>occurrences (all)<br><br>Upper respiratory tract inflammation<br>subjects affected / exposed<br>occurrences (all) | 0 / 32 (0.00%)<br>0<br><br>0 / 32 (0.00%)<br>0<br><br>1 / 32 (3.13%)<br>1 | 1 / 32 (3.13%)<br>1<br><br>2 / 32 (6.25%)<br>2<br><br>2 / 32 (6.25%)<br>2 | 2 / 30 (6.67%)<br>2<br><br>1 / 30 (3.33%)<br>1<br><br>0 / 30 (0.00%)<br>0 |
| Skin and subcutaneous tissue disorders<br>Comedone<br>subjects affected / exposed<br>occurrences (all)   | 2 / 32 (6.25%)<br>2   | 0 / 32 (0.00%)<br>0   | 0 / 30 (0.00%)<br>0   |
| Infections and infestations  |   |   |   |

|   |                        |                      |                      |
|---|------------------------|----------------------|----------------------|
| Nasopharyngitis<br>subjects affected / exposed<br>occurrences (all) | 10 / 32 (31.25%)<br>11 | 7 / 32 (21.88%)<br>9 | 7 / 30 (23.33%)<br>8 |
|---|------------------------|----------------------|----------------------|

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported